Pre-EclampsiaNCT00262093
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
An observational study of Pre-Eclampsia, run by Hadassah Medical Organization at 1 site in Israel.
Trial summary
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients. Read more about this study
- Who is it for?
- Any age, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pre-Eclampsia
- How many people
- 200 participants
- Where
- 1 siteIsrael
- Study dates
- Nov 2005to not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Every delivery
Who cannot join
- Preeclampsia or pregnancy induced hypertension
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Hadassah Medical Organization
Jerusalem, 91240
Arik Tzukert, DMD, 972 2 6776095, arik@hadassah.org.il
Hadas Lemberg, PhD, 972 2 6777572, lhadas@hadassah.org.il
About this study
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.
Read the detailed description
Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.
We intend to check the angiogenesis profile of primiparas as compared to multiparas.
- Conditions
- Pre-Eclampsia
- Keywords
- preeclampsia, sFlt1, PlGF, parity, angiogenesis
- Medical subject headings
- Pre-Eclampsia
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2005 (estimated)
- Study startNov 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pre-EclampsiaStudies of the same condition, open and under way.
- More trials run by Hadassah Medical OrganizationThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hadassah Medical Organization
- Sponsor type
- University, hospital or other
- Collaborators
- Beth Israel Deaconess Medical Center
- Investigators
- Yuval Bdolah, MD, MSc, Principal investigator, Hadassah-Hebrew University Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00262093
- Sponsor's protocol ID
- PRIMIMULTI-HMO-CTIL
- Status last verified
- Nov 2005
- First submitted
- 4 Dec 2005
- Last updated
- 20 Mar 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
- ClinicalTrials.gov ID
- NCT00262093
- Acronym / sponsor ID
- PRIMIMULTI-HMO-CTIL
- Conditions
- Pre-Eclampsia
- Keywords
- preeclampsia, sFlt1, PlGF, parity, angiogenesis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Hadassah Medical OrganizationUniversity, hospital or other
- Collaborators
- Beth Israel Deaconess Medical Center
- Study start
- Nov 2005
- First posted
- 6 Dec 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.
Detailed description
Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.
We intend to check the angiogenesis profile of primiparas as compared to multiparas.
Study design
- Observational model
- Case-control
- Time perspective
- Other
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Every delivery
Key exclusion criteria (1 listed)
- Preeclampsia or pregnancy induced hypertension
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2007.
Related trials for Pre-Eclampsia
Recruiting
Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia
Postpartum Exercise, Cardiometabolic Health
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Severe Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yuval Bdolah, MD, MSc principal investigator
Hadassah-Hebrew University Medical School
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pre-Eclampsia, run by Hadassah Medical Organization at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Mar 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yuval Bdolah, MD, MSc (972-2-5844111, ybdolah@hadassah.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2007.